Want to see SE:MCAP full AI Analyst Report?
MCAP Stock Chart & Stats
kr550.00
kr4.50(0.81%)
At close: 4:00 PM EDT
kr550.00
kr4.50(0.81%)
Day’s Range― - ―
52-Week Rangekr440.00 - kr636.00
Previous CloseN/A
Volume1.66K
Average Volume (3M)17.13K
Market Cap
kr7.96B
Enterprise Valuekr8.03B
Total Cash (Recent Filing)kr286.30M
Total Debt (Recent Filing)kr457.60M
Price to Earnings (P/E)32.9
Beta0.61
Next Earnings
Oct 23, 2026EPS Estimate
4.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.04
Shares Outstanding15,080,753
10 Day Avg. Volume23,044
30 Day Avg. Volume17,134
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)22.91
Revenue Forecast (FY)kr2.39B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthMedCap has substantially expanded its revenue base over several years, indicating sustained growth across its healthcare portfolio rather than reliance on a single short-term gain. Continued scale can strengthen operating leverage, broaden the earnings base, and support further investment in portfolio development.
Stable ProfitabilityConsistent operating margins provide evidence that MedCap’s portfolio companies are converting growth into durable profits. Maintaining roughly 15% EBIT margins across periods supports earnings resilience, creates capacity for reinvestment, and suggests the business model is not dependent solely on revenue expansion.
Strong Free Cash Flow And ReturnsStrong and growing free cash flow, combined with healthy mid-teens return on equity, indicates effective use of the group’s capital base and meaningful internal funding capacity. This supports acquisitions, operational improvements, and shareholder value creation without relying entirely on external financing.
Bears Say
Rising Total DebtAlthough leverage remains conservative, the increase in total debt raises the financial commitments attached to MedCap’s portfolio strategy. Further borrowing could reduce flexibility during weaker operating periods, increase financing costs, and make future acquisitions more dependent on sustained cash generation.
Uneven Cash ConversionFree cash flow is strong, but below-one-times operating cash flow coverage shows that accounting earnings are not converting consistently into operating cash. Persistent conversion volatility could constrain funding for acquisitions and operations, while making financial performance more sensitive to working-capital timing.
Gross Margin VolatilityThe sharp variation in gross margin reduces visibility into the underlying economics of MedCap’s portfolio companies. If the fluctuations reflect mix, reclassification, or cost variability, forecasting profitability becomes more difficult and the durability of reported earnings quality is less certain.
MedCap AB News
MCAP FAQ
What was MedCap AB’s price range in the past 12 months?
MedCap AB lowest stock price was kr440.00 and its highest was kr636.00 in the past 12 months.
What is MedCap AB’s market cap?
MedCap AB’s market cap is kr7.96B.
When is MedCap AB’s upcoming earnings report date?
MedCap AB’s upcoming earnings report date is Oct 23, 2026 which is in 10 days.
How were MedCap AB’s earnings last quarter?
MedCap AB released its earnings results on Jul 21, 2026. The company reported kr5.8 earnings per share for the quarter, beating the consensus estimate of kr4.74 by kr1.06.
Is MedCap AB overvalued?
According to Wall Street analysts MedCap AB’s price is currently Overvalued.
Does MedCap AB pay dividends?
MedCap AB does not currently pay dividends.
What is MedCap AB’s EPS estimate?
MedCap AB’s EPS estimate is 4.71.
How many shares outstanding does MedCap AB have?
MedCap AB has 15,080,753 shares outstanding.
What happened to MedCap AB’s price movement after its last earnings report?
MedCap AB reported an EPS of kr5.8 in its last earnings report, beating expectations of kr4.74. Following the earnings report the stock price went up 12.314%.
Which hedge fund is a major shareholder of MedCap AB?
Currently, no hedge funds are holding shares in SE:MCAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedCap AB
MedCap AB (publ) operates as a private equity firm, employing a diverse array of investment strategies including secondary direct deals, later-stage funding, industry consolidation, growth capital provision, engagement with middle-market and mature businesses, turnarounds, and outright buyouts. The company primarily directs its capital towards businesses within the healthcare sector, focusing on medical equipment and services, biotechnology, life sciences, and pharmaceuticals. It actively seeks unlisted, small to mid-sized companies located predominantly across Northern Europe. Equity investments typically fall within the SEK 25 million to SEK 150 million range (approximately $2.75 million to $16.51 million). Target companies generally exhibit an enterprise value and annual sales revenue between SEK 50 million and SEK 200 million ($5.90 million to $23.06 million), alongside an EBITDA of SEK 1 million to SEK 50 million ($0.11 million to $5.50 million). MedCap aims to acquire ownership stakes of 20% to 50% in its portfolio entities, financing these through its own capital, loans, and direct balance sheet investments. Established in 2001, the firm maintains its headquarters in Stockholm, Sweden.
Technical Analysis
Getinge
―
Vitrolife AB
―
Xvivo Perfusion AB
―
Sectra AB Class B
―
Sedana Medical AB
―